[1]孙志成,王舒琦,刘 昭,等.利益相关者视角下创新药物筹资支付路径研究[J].卫生经济研究,2022,39(3):9-12,17.
　SUN Zhi-cheng,WANG Shu-qi,LIU Zhao,et al.Research on the Pathway of Innovative Drug Financing and Payment from the Perspective of Stakeholders[J].Journal Press of Health Economics Research,2022,39(3):9-12,17.
点击复制

利益相关者视角下创新药物筹资支付路径研究

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年3期
页码:
9-12,17
栏目:
筹资与支付
出版日期:
2022-03-01

文章信息/Info

Title:
Research on the Pathway of Innovative Drug Financing and Payment from the Perspective of Stakeholders
作者:
孙志成1; 王舒琦2; 3; 刘 昭2; 3; 刘跃华 2; 3; 赵 琨2; 3
1.清华大学医院管理研究院，广东 深圳 518055
2.清华大学万科公共卫生与健康学院，北京 100084
3.清华大学健康中国研究院，北京 100084
Author(s):
SUN Zhi-cheng;  WANG Shu-qi;  LIU Zhao;  LIU Yue-hua;  ZHAO Kun
Institute for Hospital Management of Tsinghua University, Shenzhen Guangdong 518055, China
关键词:
创新药物; 利益相关者; 筹资路径
Keywords:
innovative drugs;  stakeholders;  financing pathway
分类号:
R95
文献标志码:
A
摘要:
应用利益相关者理论，分析患者、医保方、医疗方、药品生产商在创新药物筹资领域的关系与各自面临的困境，借鉴国际经验，提出构建我国创新药物多元筹资体系的建议：协调各方利益诉求，以医保为切入口，构建多层次医疗保障体系，同时丰富医疗保险产品、开源节流医保基金、设立药物研发激励与补偿机制、鼓励开展早期谈话和试点项目，逐步破解创新药物的筹资支付难题。
Abstract:
This study applied stakeholder theory to analyze the relationship between patients, medical insurance providers, medical services providers, and drug manufacturers in the field of innovative drug financing, together with their respective problems. Drawing on international experience, this study proposed suggestions to build a multi-funding system for innovative drugs in China: Firstly, coordinating the interests of all parties and adopting medical insurance as entry point, so as to build a multi-level medical insurance system and develop a variety of medical insurance products. Secondly, enhancing multi-channel medical insurance financing and reducing unreasonable medical insurance expenditures. Thirdly, setting up incentive and compensation mechanisms for drug research and development. And last, encouraging early talks and pilot projects. These suggestions may help gradually solve the problems faced by financing and payment of innovative drugs.

参考文献/References:

[1] 陶秀梅，董江萍，黄蕾，等.刍议创新药物研发的生态环境与创新药物研发[J].中国药学杂志，2016，51（7）：592-597.
[2] 伍琳，陈永法.我国创新药物研发能力的国际比较及成因分析[J].中国卫生政策研究，2017，10（8）：23-28.
[3] 武霞，邵蓉.风险投资视角下的创新药物研发激励体系模型研究[J].中国新药杂志，2020，29（20）：2286-2293.
[4] 褚淑贞，王恩楠，余紫君.创新药物市场准入政策环境研究——基于利益相关者视角[J].中国卫生政策研究，2017，10（8）：29-33.
[5] 武霞，柯朝静，邵蓉.创新药物风险投资策略现状研究[J].中国新药杂志，2020，29（21）：2459-2464.
[6] 刘跃华，刘昭，张萌，等.英国癌症药物基金改革及对医保创新药支付政策的启示[J].中国卫生政策研究，2020，13（7）：52-57.
[7] Freeman RE.Strategic management:a stakeholder approach[M]. Cambridge University Press, 1984.
[8] 黄如方，邵文斌.中国罕见病药物可及性报告[R].上海，2019.
[9] 孙东雅.发展商业健康保险助力健康中国建设[J].中国医疗保险，2020（12）：27-29.
[10] 方鹏骞，赵圣文，乐曲，等.我国高值药品医疗保险管理策略探讨[J].中国卫生事业管理，2017，34（11）：826-828.
[11] Zhu Da-long,Gan Sheng-lian,et al.Dorzagliatin monotherapy in Chinese patients with type 2 diabetes:A dose-ranging,randomised, double-blind,placebo-controlled, phase 2 study[J].The Lancet.Diabetes & Endocrinology,2018,6(8):627-636.
[12] Hu D,Sun L,Fu P,et al.Prevalence and risk factors for type 2 diabetes mellitus in the Chinese adult population:the InterASIA Study[J].Diabetes Res Clin:Pract, 2009,84(3):288-295.
[13] MIT Center for Biomedical Innovation.Designing Financial Solutions to Ensure Affordable Access to Cures:an Overview of the MIT FoCUS project[R].Boston:2019.
[14] E.Hannaa,M.Toumia,C.Dussart，et al.Funding breakthrough therapies:A systematic review and recommendation[J].Health Policy, 2018 (122)：217-229.
[15] Royalty Pharma.Royalty Monetization.Available at:https://www.royaltypharma.com/royalty-monetization.
[16] 许飞琼.中国多层次医疗保障体系建设现状与政策选择[J].中国人民大学学报，2020，34（5）：15-24.
[17] 孙圆圆，魏靖哲，蒋蓉，等.发挥医保对医药创新引领作用的路径研究:建立医保创新药物发展基金的设想[J].中国卫生经济，2018，37（12）：33-36.

相似文献/References:

[1]江蒙喜,李卫平.我国公立医院混合所有制改革的利益相关者分析[J].卫生经济研究,2017,(07):18.
[2]卢 慧,魏 来,余昌胤,等.分级诊疗相关利益主体的损益分析[J].卫生经济研究,2018,(02):31.
[3]舒 茜,姚峥嵘,王艳翚,等.药品带量采购政策的利益相关者分析[J].卫生经济研究,2019,(08):8.
　SHU Qian,YAO Zheng-rong,WANG Yan-hui,et al.Stakeholder Analysis of Drug Consumption Policy[J].Journal Press of Health Economics Research,2019,(3):8.
[4]李赛赛,徐 伟,王煜昊,等.创新药物医保目录准入研究[J].卫生经济研究,2019,(10):40.
　LI Sai-sai,XU Wei,WANG Yu-hao,et al.Research on Access to the List of Innovative Medicines[J].Journal Press of Health Economics Research,2019,(3):40.
[5]冷楠楠,邱英鹏,赵羽西,等.冠脉支架集中带量采购对医疗服务供给的潜在影响分析[J].卫生经济研究,2022,39(5):1.
　LEN Nan-nan,QIU Ying-peng,ZHAO Yu-xi,et al.Analysis of the Potential Impact of the Policy of Centralized Procurement of Coronary Stents on the Provision of Medical Services[J].Journal Press of Health Economics Research,2022,39(3):1.
[6]雷 桃,杨金侠,洪梦园,等.医保支付促进慢性病防控策略分析 ——基于利益相关者理论[J].卫生经济研究,2022,39(8):38.
　LEI Tao,YANG Jingxia,HONG Mengyuan,et al.Analysis of Medical Insurance Payment to Promote the Prevention and Control of Chronic Diseases ——Based on Stakeholder Theory[J].Journal Press of Health Economics Research,2022,39(3):38.
[7]林岱衡,陈逸桐,谭清立,等.我国长护险失能评估的典型做法及优化策略[J].卫生经济研究,2023,40(7):32.
　LIN Daiheng,CHEN Yitong,TAN Qingli,et al.Typical Practices and Optimization Strategies for Disability Assessment of Long-term Care Insurance in China[J].Journal Press of Health Economics Research,2023,40(3):32.
[8]周正荣,汪卓赟,王 玉,等.推广三明医改经验对各方利益相关者的影响及其阻滞因素研究[J].卫生经济研究,2025,42(06):5.
　ZHOU Zhengrong,WANG Zhuoyun,WANG Yu,et al.Study on the Impact of Promoting Sanming Medical Reform Experience on Stakeholders and its Hindering Factors[J].Journal Press of Health Economics Research,2025,42(3):5.

更新日期/Last Update: 2022-03-01